Becton, Dickinson and Company $BDX Position Trimmed by Clarkston Capital Partners LLC

Clarkston Capital Partners LLC lessened its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 2.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 366,250 shares of the medical instruments supplier’s stock after selling 10,585 shares during the quarter. Becton, Dickinson and Company makes up 1.6% of Clarkston Capital Partners LLC’s investment portfolio, making the stock its 21st largest holding. Clarkston Capital Partners LLC’s holdings in Becton, Dickinson and Company were worth $71,078,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Imprint Wealth LLC purchased a new position in Becton, Dickinson and Company during the 3rd quarter valued at about $25,000. Steph & Co. grew its stake in shares of Becton, Dickinson and Company by 95.6% in the 4th quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock valued at $26,000 after buying an additional 65 shares in the last quarter. Accredited Wealth Management LLC grew its stake in shares of Becton, Dickinson and Company by 77.8% in the 3rd quarter. Accredited Wealth Management LLC now owns 160 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 70 shares in the last quarter. WPG Advisers LLC grew its stake in shares of Becton, Dickinson and Company by 64.2% in the 4th quarter. WPG Advisers LLC now owns 156 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 61 shares in the last quarter. Finally, Kohmann Bosshard Financial Services LLC bought a new stake in shares of Becton, Dickinson and Company in the 4th quarter valued at approximately $32,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Insider Buying and Selling

In other Becton, Dickinson and Company news, CEO Thomas E. Polen, Jr. sold 2,764 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $146.35, for a total transaction of $404,511.40. Following the completion of the sale, the chief executive officer owned 110,163 shares of the company’s stock, valued at $16,122,355.05. This represents a 2.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of the company’s stock in a transaction that occurred on Wednesday, June 10th. The stock was sold at an average price of $151.48, for a total value of $166,628.00. Following the sale, the executive vice president directly owned 14,272 shares of the company’s stock, valued at $2,161,922.56. The trade was a 7.16% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 4,013 shares of company stock valued at $593,434 in the last ninety days. Company insiders own 0.40% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on BDX shares. Wells Fargo & Company boosted their price target on Becton, Dickinson and Company from $157.00 to $161.00 and gave the company an “equal weight” rating in a research note on Friday, May 8th. Argus lowered their price target on Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating for the company in a research note on Monday, March 23rd. Zacks Research raised Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a research note on Friday, April 10th. Evercore boosted their price target on Becton, Dickinson and Company from $180.00 to $190.00 in a research note on Thursday, May 7th. Finally, Weiss Ratings cut Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. Seven research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Becton, Dickinson and Company currently has an average rating of “Hold” and a consensus price target of $182.73.

Becton, Dickinson and Company Stock Down 0.8%

Shares of Becton, Dickinson and Company stock opened at $146.13 on Friday. The stock has a market capitalization of $40.27 billion, a P/E ratio of 37.00, a PEG ratio of 10.43 and a beta of 0.22. The company has a quick ratio of 0.55, a current ratio of 0.94 and a debt-to-equity ratio of 0.62. The stock has a 50 day moving average price of $150.00 and a two-hundred day moving average price of $174.05. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $187.35.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.77 by $0.13. The firm had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.67 billion. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The company’s revenue was up 5.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.35 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Equities analysts expect that Becton, Dickinson and Company will post 12.61 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th will be given a dividend of $1.05 per share. The ex-dividend date of this dividend is Tuesday, June 9th. This represents a $4.20 dividend on an annualized basis and a yield of 2.9%. Becton, Dickinson and Company’s dividend payout ratio is presently 106.33%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.